

Antibody-Drug Conjugates: An Emerging Modality for the Treatment of Cancer




Image courtesy of
Hans-Peter Gerber,
Frank E. Koehn and
Robert T. Abraham,
Pfizer

www.nyas.org/ADCs

Conventional anticancer therapies lack specificity, resulting in toxicity to healthy tissue. Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent is chemically linked to an antibody that recognizes a tumor-associated antigen. The ADC platform includes a growing repertoire of cytotoxic payloads, linker technologies and conjugation methods; two ADCs are FDA-approved and over 30 are in clinical development. This symposium highlight advances in ADC research, clinical development and regulatory perspectives. Topics span early phase research focused on development of novel linker-payload and conjugation chemistries, clinical concepts and development of biomarkers and patient selection strategies.

Organizers

Mercedes Beyna, MS, Pfizer
Nahor Haddish-Berhane, PhD, Pfizer
Jennifer Henry, PhD, The New York Academy of Sciences
Mauricio Leal, PhD, Pfizer
Puja Sapra, PhD, Pfizer
Dhaval K. Shah, PhD, The State University of New York at Buffalo

Speakers

Ho Sung Cho, PhD, Ambrx, Inc.
Nahor Haddish-Berhane, PhD, Pfizer
Sara Hurvitz, MD, UCLA Medical Center
Omar Kabbarah, PhD, Genentech Inc.
Puja Sapra, PhD, Pfizer
Melissa M. Schutten, DVM, PhD, DACVP, Genentech Inc.
Peter D. Senter, PhD, Seattle Genetics, Inc.
Dhaval K. Shah, PhD, The State University of New York at Buffalo
Stacey S. Shord, PharmD, BCOP, FCCP, Food and Drug Administration

Presented by the **Biochemical Pharmacology Discussion Group** at the **New York Academy of Sciences**

The **Biochemical Pharmacology Discussion Group** is proudly supported by



Mission Partner support for the Frontiers of Science program provided by **Pfizer**

JAN
28
8:30 AM-
4:30 PM

Location

The New York
Academy of Sciences
7 World Trade Center
250 Greenwich Street
40th Floor
New York, NY 10007-2157

Sponsorship Opportunities

please contact
Perri Wisotsky
at pwisotsky@nyas.org
or 212.298.8642